Introduction {#S0001}
============

Cesarean delivery (CD) has proven to be highly beneficial for women and newborns, and the rates of delivery by CD have witnessed a steady increase over the past few decades.[@CIT0001] The rate of CD in China is one of the highest in the world.[@CIT0001],[@CIT0002] The main complications of CD include pain, wound separation/infection, gastrointestinal dysfunction, and deep venous thrombosis.[@CIT0003] Pain is one of the most important complications since it serves as a risk factor for other complications and is the main cause of anxiety and depression among patients.[@CIT0004]

In recent times, various protocols have been introduced for enhanced recovery after surgery (ERAS). These ERAS protocols encompass multimodal perioperative management principles to minimize surgical stress and potential complications, accelerate patient recovery, and achieve effective analgesia.[@CIT0005] ERAS protocols have been developed to address perioperative complications that cannot be resolved by a single method alone.[@CIT0006] The ERAS protocols involve multiple factors that work in conjunction to reinforce each other and reduce stress and cytokine levels, promote trauma repair, and reduce the rate incidence of complications.[@CIT0007],[@CIT0008] Excitingly, ERAS guideline for CD has been published, which included inclusive perioperative recommendations with primarily a maternal focus.[@CIT0009]--[@CIT0011] However, the concern of pain relief has not been prominent. Therefore, at our medical center, we developed a feasible ERAS protocol that combines recommendations based on these guidelines as well as our experience in our clinical practice.

In this prospective-randomized controlled study, we sought to test whether the implementation of ERAS in patients undergoing elective CD would be beneficial in the management of postoperative pain, hospital stay, hospitalization costs, and complications.

Materials and Methods {#S0002}
=====================

Study Design {#S0002-S2001}
------------

The current study was planned as a randomized-controlled prospective trial. The study protocol was approved by the ethics committee of the Third Affiliated Hospital of Sun Yat Sen University, Guangzhou, China on August 8, 2019. This study has been registered in the Chinese Clinical Trial Registry (registration no.: ChiCTR1900025456, registered 26 August 2019, [<http://www.chictr.org.cn/showproj.aspx?proj=42067>]{.ul}). Written informed consent was obtained from all participants of the study.

Study Design and Participants {#S0002-S2002}
-----------------------------

The inclusion criteria for the study were as follows: age of 25--45 years, gestation age \>38 weeks, scheduled for elective cesarean delivery under combined spinal and epidural anesthesia (CSEA), and surgery performed between September 2019 and November 2019. Patients were excluded from the study if they met the following criteria: history of serious dysfunction of cardiovascular, coagulation, and metabolism; contraindications to morphine or CSEA use; opioid dependence; history of gastrointestinal emptying disorders, inability to conform to the ERAS strategy, need for other surgeries along with surgery, and refusal to participate in the study.

Sample Size and Randomization {#S0002-S2003}
-----------------------------

The calculation of the required sample size was based on postoperative pain intensity at rest and on motion, which was the primary outcome. Our preliminary study showed that the ratio of postoperative pain of VAS grade \>3 at rest and on motion in 24 h was 34% and 65% in the control group and 17% and 42% in the ERAS group, respectively. For power of 0.8 and α = 0.05, with a dropout rate of 20%, the sample size was calculated to be 119 and 84, respectively. Therefore, the sample size required in this study was determined to be at least 119 in each group.

The patients were divided into two groups: ERAS group and control group in 1:1 ratio by a computer-generated randomization sequence. According to the group assigned, they were managed with the ERAS protocol or routine protocols separately. All the enrolled participants were provided information regarding the study during their antenatal visits. The components of the two protocols are detailed in [Table 1](#T0001){ref-type="table"}. Only details of the protocol for their respective groups were provided to the patients. On admission, care was taken to ensure that the patients of different groups were not in the same ward.Table 1Routine Protocol and ERAS ProtocolRoutine ProtocolERAS ProtocolEducation/CounselingPerioperative information was not provided in advance.Information on perioperative procedure, pain management plan, the necessity of early feeding and mobilization, lactation support services, discharge criteria, follow-up schedule, etc.Preoperative oral intakeFasting from midnight before surgeryFluid up to 2 h prior to surgery\
Solid foods up to 6 h prior to surgeryStandard anesthetic protocolReceived CSEA, spinal 5% ropivacaine 12.5--13.5mg, and epidural 1% lidocaine 3mL, before PCEA started.\
Dexmedetomidine 0.5 μg/kg pump was administration only if heart rate \>90 beats/min or anxiety, and without any contraindications.Received CSEA, the same as the routine protocol.\
Dexmedetomidine 0.5 μg/kg pump was recommended after childbirth. It was avoided if there were contraindications, heart rate \<60 beats/min or systolic blood pressure \<100mmHg.Postoperative pain managementPCEA for 2 days; 2 mg morphine initial bolus; 6--7mg morphine and 13.5 mg ropivacaine diluted into 100 mL in the pump, 2 mL/h basal rate, 0.5 mL bolus with a 15-minute lockoutStrict 6mg morphine in the pump; remaining points same as the routine protocolExtra analgesicsWhen pain was of VAS\>3, and the patient requested extra analgesics, Tramadol 100 mg intramuscular injection was administeredThe same as routine protocolPrevention of PONVTropisetron 5mg at the end of the surgery.Tropisetron 5 mg immediately after the childbirth; other antiemetics as neededIntraoperative oxytocinOxytocin 20 U dilute to 500 mL, immediately after cord clamping, continuous infusion 1--2 h\
Carboprost tromethamine 250 μg intramuscular injection, determined by the obstetricianOxytocin controlled at 40--60 drop/min\
Remaining points same as the routine protocolProphylactic antibioticsAntibiotics administration after cord clamping immediately.Same as the routine protocolPerioperative fluid and blood pressure managementPreferred crystalloid infusion to reduce hypotension. Phenylephrine 50μg/bolus if necessary.Avoid overhydration. Both ﬂuids and vasopressors to counteract hypotension. Prophylactic phenylephrine 50μg followed by CSEA.Preventing intraoperative hypothermiaCovering bedding without warm air blower.The bedding was warmed with warm air blower before surgery.Postoperative oral intakeUntil the return of bowel function, such as ﬂatus or stoolsEarly oral intake, started 2h after surgery, start with light diet less than 200 mL, and then gradually increased according to gastrointestinal tolerancePostoperative mobilizationMobilization as per patient's discretionUmbilical self-massage according to the tolerance.\
Actively turned over 6 hours after surgery.\
Mobilization at the bedside on the first day after surgery, followed by walking in the ward.Skin to skin and breastfeedingAs per patient's discretion, mostly after the anesthetic wore offRecommend early skin-to-skin contact with the newborn, immediately after back to the ward.\
Breastfeeding within 1 hour after the surgery, according to the baby's needs[^2]

Data Collection {#S0002-S2004}
---------------

The perioperative data of the patients regarding the following parameters were collected: demographic characteristics (age, weight, and height), ASA grade, parity, gestational condition, preoperative complications, and blood loss. The amount and the number of drugs used during the surgery were recorded, such as vasoactive agents, carboprost tromethamine, dexmedetomidine, and antiemetics. Further, the details regarding the patient-controlled epidural analgesia (PCEA) formula, length of stay, postoperative length of stay, and hospitalization, and anesthesia costs were noted. The patients were asked to rate their pain intensity at rest and motion according to the visual analog scale (VAS) on the first and second postoperative days. Additionally, the severity of nausea, vomiting, and pruritus was evaluated before PCEA was removed. Patient satisfaction regarding the overall hospitalization experience was graded according to the VAS.

Outcomes {#S0002-S2005}
--------

The primary outcome was postoperative pain intensity, as measured using the VAS. The secondary outcomes assessed were perioperative discomfort, satisfaction score, length of stay, and hospitalization cost.

Statistical Analysis {#S0002-S2006}
--------------------

Statistical analyses were conducted using SPSS v22.0 software package (SPSS, Chicago, IL, USA). The data were expressed as mean ± standard deviation or proportions. Parametric data were analyzed by analysis of variance, nonparametric data with the Mann--Whitney *U*-test, and the proportions with Fisher exact test. For all analyses, *P* \<0.05 was set for statistical significance.

Results {#S0003}
=======

In all, 240 parturients were enrolled in this study. Some of the patients were excluded from the study: 8 and 10 patients in the ERAS group and control group, respectively, were excluded due to unexpected emergency CD; 6 patients in the control group refused to follow the routine protocols. Thus, the final analysis included 104 patients in the control group and 112 patients in the ERAS group ([Figure 1](#F0001){ref-type="fig"}). Comparison of the baseline patient characteristics showed that both groups were similar in terms of the preoperative ASA score, parity, gestational week, single or twin gestation, preoperative complications, and blood loss ([Table 2](#T0002){ref-type="table"}).Table 2Preoperative Characteristics of the PatientsCharacteristicsGroup Control n=104Group ERAS n=112P valueAge (years)32.59 ± 4.1433.21 ± 4.490.295Body mass index (kg/m^2^)27.01 ± 3.2127.09 ± 3.330.860**ASA score** 131 (29.81%)25 (22.32%)0.218 273 (70.19%)87 (77.68%)**Parity** 128 (26.92%)38 (33.93%)0.302 268 (65.38%)68 (60.71%)0.485 3 and more8 (7.84%)6 (5.36%)0.585Gestational week39.03 ± 0.9138.96 ± 0.910.602**Gestation** Single100 (96.15%)106 (94.64%)0.750 Twins4 (3.85%)6 (5.36%)**Preoperative complications** Thalassemia27 (25.96%)22 (19.64%)0.330 Hepatitis14 (13.46%)22 (19.64%)0.274 Diabetes16 (15.38%)20 (17.86%)0.716**Blood loss during cesarean delivery** ≤500mL62 (59.62%)70 (62.50%)0.678 \>500mL42 (40.38%)42 (37.50%)[^3] Figure 1Patient enrollment and randomization.

Postoperative Pain VAS Score {#S0003-S2001}
----------------------------

The same anesthesia protocol was applied for all patients, except for the PCEA formula. Patients in the ERAS group received PCEA with 6 mg morphine, but only 55 patients in the control group received morphine of 6 mg (100% vs. 52.88%, *P*\<0.01); the others required 7 mg.

Within 48 h of the surgery, assessment of postoperative pain was completed for all patients ([Figure 2](#F0002){ref-type="fig"}). The VAS scores of pain at both postoperative 24 h and 48 h was significantly lower in the ERAS group than in the control group, both at rest and on motion ([Table 3](#T0003){ref-type="table"}).Table 3Postoperative Pain VASCharacteristicsGroup Control n=104Group ERAS n=112P valueRest in 24 h3.50 ± 1.762.46 ± 1.58\<0.001Motion in 24 h4.74 ± 1.903.38 ± 2.10\<0.001Rest in 48 h2.60 ± 1.572.00 ± 1.650.007Motion in 48 h3.50 ± 1.652.77 ± 2.010.004Requirement of extra analgesics1 (0.96%)1 (0.89%)1.000[^4] Figure 2Visual analog scale (VAS) scores of pain in the two groups at rest and motion on the first and second postoperative days.

Further analysis revealed that during the first 24 h after the CD, significantly less patients in the ERAS group had pain of grade \>3 as per the VAS during rest and motion. At 48 h after surgery, the number of patients with pain of VAS grade \>3 on motion was significantly higher in the control group than in the ERAS group. ([Figure 3](#F0003){ref-type="fig"}).Figure 3The proportion of postoperative pain of visual analog scale (VAS) grade \>3 in the two groups.

Only one patient in each group required extra analgesics (tramadol 100mg intramuscular injection); therefore, the difference in the requirement of extra analgesics was not significant ([Table 3](#T0003){ref-type="table"}).

Intraoperative and Postoperative Conditions ([Table 4](#T0004){ref-type="table"}) {#S0003-S2002}
---------------------------------------------------------------------------------

The dosage of conventional oxytocin and carboprost tromethamine was similar in both groups. The requirement of intraoperative dexmedetomidine in the ERAS group was considerably high.Table 4Intraoperative and Postoperative ConditionsCharacteristicsGroup Control n=104Group ERAS n=112P value**Intraoperative** Carboprost tromethamine82 (78.85%)76 (67.86%)0.091 Dexmedetomidine33 (31.73%)66 (58.93%)\<0.001 Nausea23 (22.12%)3 (2.68%)\<0.001 Vomiting6 (5.77%)1 (0.89%)0.058 Shivering8 (7.69%)9 (8.04%)1.000 Hypotension35 (33.65%)31 (27.08%)0.377**Postoperative discomfort in 48 h** Nausea1 (0.96%)4 (3.57%)0.371 Pruritus25 (24.04%)28 (25.00%)0.876

During the operation, only 3 patients in the ERAS group experienced nausea, indicating that the incidence of nausea was significantly lower in the ERAS group than that in the control group. The incidence of vomiting was greater in the control group, although the intergroup difference was not significant (*P* =0.058). Both groups had similar incidences of shivering and hypotension.

During the first 48 h after the operation, the incidence of nausea remained low in both the groups, without any significant difference between the two groups. There were no instances of postoperative vomiting. The incidence of pruritus in both groups was similar, with no significant intergroup difference.

Satisfaction VAS, Length of Stay and the Cost of Hospitalization ([Table 5](#T0005){ref-type="table"}) {#S0003-S2003}
------------------------------------------------------------------------------------------------------

The mean of patient satisfaction according to the VAS score in both groups was above 8, but was significantly higher in the ERAS group.Table 5Satisfaction VAS, Length of Stay, and the Cost of HospitalizationCharacteristicsGroup Control n=104Group ERAS n=112P valueSatisfaction VAS8.12 ± 1.088.42 ± 0.760.016Length of stay (d)4.61 ± 0.644.67 ± 0.490.412Postoperative length of stay (d)3.42 ± 0.553.45 ± 0.640.775Average cost of hospitalization (RMB/d)2140.4 ± 335.41568.2 ± 303.8\<0.001The cost of anesthesia (RMB)1047.9 ± 221.11045.6 ± 212.80.937

While the length of stay and postoperative length of stay were comparable in the two groups, there were no intergroup differences in the cost of anesthesia. However, the average daily hospitalization cost was significantly lower in the ERAS group than in the control group.

Discussion {#S0004}
==========

This prospective-randomized controlled trial demonstrated that ERAS protocols were useful in CD to alleviate postoperative pain, decrease the incidence of intraoperative complications such as nausea, improve maternal satisfaction, and reduce the average cost of hospitalization. However, the application of the ERAS protocol did not reduce the length of stay or incidence of other perioperative complications.

Pain is one of the main concerns of patients who undergo surgery. Effective perioperative analgesia is a key factor in facilitating postoperative function recovery and in successfully implementing the ERAS program. An analysis of pain severity over a hundred different surgical procedures revealed that post-CD pain intensity was one of the highest.[@CIT0012] Suboptimal analgesia has been shown to be associated with the failure of other components of ERAS, including delayed mobilization, delayed functional recovery, difficulties in breastfeeding and providing intimate contact to newborns, postpartum depression, and persistent pain.[@CIT0013] Adequate postoperative analgesia is an important and integral component of ERAS protocol, which is achieved via a multidisciplinary approach. Multimodal analgesia refers to the approach of using a combination of drugs acting under different mechanisms as well as different interventional modalities to optimize analgesia and minimize side effects.[@CIT0014],[@CIT0015] Multimodal analgesia has been shown to have a positive effect in many non-obstetric surgical procedures, such as urologic, gastrointestinal, and orthopedic surgeries.[@CIT0015],[@CIT0016] However, the effect of multimodal analgesia in CD still remains controversial. Nonsteroidal anti-inflammatory drugs (NSAIDs) are usually incorporated in multimodal analgesic protocols because of their relatively milder adverse effects and efficacy in anti-inflammatory and relief of visceral pain. Some investigators have shown that acetaminophen or NSAIDs could decrease the requirement of postoperative opioids,[@CIT0017] while others were of the opposite view.[@CIT0018],[@CIT0019] Transversus abdominis plane (TAP) blocks helped provide improved postoperative analgesia and reduce morphine consumption in patients who underwent CD under general anesthesia,[@CIT0020] but not in those who received intrathecal morphine.[@CIT0021] Compared to the standard analgesic regimen, TAP blocks do not have any effect in reducing the incidence or severity of chronic postsurgical pain after CD.[@CIT0022]

In our study, neither perioperative oral and intravenous analgesics nor nerve blocks were requested designedly, and the same CSEA protocol was applied for all patients. PCEA was a countermeasure to withstand the wide inter-individual variability in post-CD pain. Although less morphine was used in the ERAS group (6 mg vs. 6--7 mg), the mean of postoperative pain VAS scores was significantly lower, and patients with obvious pain (VAS\>3) were significantly fewer than that in the control group. Therefore, it could be inferred that pain relief should be attributed to the overall ERAS strategy rather than morphine. Recent studies have shown that active patient participation during the perioperative period had a positive impact on the postoperative outcomes, including pain relief.[@CIT0015],[@CIT0023] In addition, dexmedetomidine was believed to decrease VAS scores.[@CIT0024] The reduced pain in the ERAS group may be attributed to the increased administration of dexmedetomidine in that group. Our results suggested that ERAS protocol can be employed as an alternative to analgesics in the future. However, there was another surprising finding that although a number of patients reported pain of VAS\>3, only one patient in each group requested for extra analgesics, which was considered to be avoided as far as possible. The reason might include that with outdated or traditional concepts, intrapartum and postpartum pain are considered unavoidable, and analgesics are considered to have adverse effect on infants through breastfeeding. Although these notions have gradually changed with preoperative education, it still remains deeply ingrained in the public mindset; therefore, better publicity and education of people regarding the newer concepts are warranted.

Increased analgesic effect is always accompanied by unfavorable adverse effects. Nausea, vomiting, and pruritus are the most common complications of CD, especially in patients treated with neuraxial opioids.[@CIT0025] The risk of such complications has been reported to be lower with low doses of intrathecal morphine.[@CIT0026] Further, hypotension is one of the triggers of intraoperative nausea and vomiting in the mother. Currently, phenylephrine is considered as the optimal vasopressor to prevent hypotension since it is associated with a low incidence of intraoperative nausea and vomiting.[@CIT0027],[@CIT0028] Another complication, chills, has a complex and multifactorial etiology, including loss of body heat, response to pain, stimulation of the sympathetic nervous system, and anxiety. Further, more than 60% patients undergoing CD under spinal anesthesia develop hypothermia.[@CIT0029] Active warming helps improve hypothermia, thereby enhancing patient satisfaction and decreasing the length of stay after CD.[@CIT0030] As is the case with other surgeries, recent ERAS protocols for CD advocate the maintenance of perioperative normothermia.[@CIT0010] Dexmedetomidine is recommended worldwide for the management of chills and cardiovascular response.[@CIT0031]--[@CIT0033] Although the guidelines from ACOG do not the use of any preoperative sedatives,[@CIT0009] some studies have shown that the use of dexmedetomidine is effective in preventing adverse reactions, such as postoperative pain, shivering, nausea, vomiting, and chest congestion, especially those introduced by carboprost tromethamine,[@CIT0034]--[@CIT0036] as well as alleviating postpartum depression.[@CIT0037] Moreover, it has been proven safe for both mother and infant when used as an intravenous adjuvant during neuraxial anesthesia in parturients undergoing CD.[@CIT0038],[@CIT0039] Furthermore, in our practice, we have noted that low-dose dexmedetomidine (0.5 μg/kg) does not cause significant sedation in the mother or neonate; skin-to-skin contacting with the newborn, breastfeeding, and postoperative motion would not be disturbed.

Traditionally, patients are asked to fast for at least 12 h before the surgery to prevent vomiting and pulmonary aspiration after the surgery. However, recent studies have shown that reducing the fasting time not only reduced the extent of preoperative thirst, hunger, and insulin resistance, but also mitigated the anxiety and promote patient satisfaction.[@CIT0040],[@CIT0041] For the parturients awaiting elective caesarean, a short fasting time was associated with normal gastric emptying and safe.[@CIT0042] The multimodal beneficial effects of ERAS not only alleviate the concerns regarding the use of analgesics but also offer other advantages such as fetal protection, prevention of coagulopathy or blood loss, reduced risk of postpartum depression, and enhanced patient comfort.

Patient satisfaction is an important aspect of the assessment of medical services. Various factors can reduce patient satisfaction score. Apart from pain, adverse reactions, and wound healing, maternal concerns also include support from family and medical staff, the success of breastfeeding, and experience of skin-to-skin with the newborn.[@CIT0043] The implementation of an ERAS protocol is both a desirable and comprehensive solution to these problems. Furthermore, the application of ERAS enhances physician--patient communications, which would in turn help improve compliance, reduce anxiety, and enhance confidence.

The length of hospital stay is an important indicator of the outcome of using ERAS and the most visual indicator of recovery speed. Several studies recommend that with the application of the ERAS protocol, the median length of hospital stay could be reduced by 30% or at least 2 days in patients undergoing abdominal surgery, without increasing the risk of readmission.[@CIT0016],[@CIT0044],[@CIT0045] The application of ERAS in CD contributed to a reduction of 0.5--1.5 days in postoperative length of stay.[@CIT0046] In our study, the length of hospital stay and length of postoperative hospital stay in both groups were around 4.6 d and 3.4 d, respectively, which meant that the differences between the two groups were not significant. There may be several reasons for this. First, CD is widely used and relatively mature, and the incidence of postoperative complications has been very low at our medical center. Secondly, due to financial requirements such as insurance and reimbursement system, the length of stay for CD is already reduced to as low as possible and further reduction may be difficult. The reduction in the overall hospitalization costs reported previously was based on the reduction in the length of hospital stay.[@CIT0015],[@CIT0047],[@CIT0048] With respect to the average cost of daily hospitalization, few studies have shown that ERAS protocol is beneficial. Since ERAS involves the use of various treatment approaches, drugs, and medical care modalities, the average daily cost of implementing this protocol may not differ significantly from or may be slightly higher than that of routine protocols. However, our study revealed that the average daily cost in the ERAS group was significantly lower than that in the control group. These results are encouraging and would greatly promote the enthusiasm of medical professionals, patients, and insurance institutions towards the application of ERAS protocols. One of the reasons for this may be the improved comfort, which in turn would reduce the need for additional treatment and care. This would result in various advantages such as a reduction in the need for care workers because of the early postoperative mobility, decrease in the requirement of fluid infusion due to the early oral intake, and reduction in the extent of medical care for the newborn because of early skin-to-skin contact and breast-feeding. Further, the implementation of ERAS protocols helps enhance patients' understanding of the perinatal period, increases their sense of control, and confidence.

Our study has a few limitations. First, we did not include long-term evaluation of the prognosis, which would require sufficient post-discharge follow-up and/or community health care data. Second, a wider repertoire of adverse reactions and complications could be included in the analysis, since the popularization of ERAS warrants attention to not only familiar complications but also less harmful and uncommon adverse reactions. Finally, it may be possible to include fetal parameters in the analysis of the impact of ERAS on the fetus. We intend to conduct further research and analysis to address these issues.

Conclusion {#S0005}
==========

In conclusion, the implementation of ERAS protocols in patients undergoing elective CD significantly reduced postoperative pain, facilitated perioperative pain management, reduced the incidence of intraoperative nausea as well as the average cost of hospitalization, and improved patient satisfaction. However, our results did not show any advantages of using ERAS protocols in terms of the length of stay and other perioperative discomforts. Nevertheless, considering the benefits, we recommend that it would be worthwhile to encourage the widespread implementation of ERAS protocols in patients undergoing elective CD.
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